63 related articles for article (PubMed ID: 872127)
21. Cytologic appearance of cells dissociated from rat colon and their separation by isokinetic and isopyknic sedimentation in gradients of Ficol.
Pretlow TP; Stinson AJ; Pretlow TG; Glover GL
J Natl Cancer Inst; 1978 Dec; 61(6):1431-8. PubMed ID: 281552
[TBL] [Abstract][Full Text] [Related]
22. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates.
Royuela M; Arenas MI; Bethencourt FR; Sánchez-Chapado M; Fraile B; Paniagua R
Eur Cytokine Netw; 2001; 12(4):654-63. PubMed ID: 11781193
[TBL] [Abstract][Full Text] [Related]
23. Growth in semisolid agar of prostate cancer cells obtained from bone marrow aspirates.
Ahmann FR; Woo L; Hendrix M; Trent JM
Cancer Res; 1986 Jul; 46(7):3560-4. PubMed ID: 3708587
[TBL] [Abstract][Full Text] [Related]
24. CD44 Expression in Benign and Neoplastic Human Prostates.
Dhir R; Gau JT; Krill D; Bastacky S; Bahnson RR; Cooper DL; Becich MJ
Mol Diagn; 1997 Sep; 2(3):197-204. PubMed ID: 10462610
[TBL] [Abstract][Full Text] [Related]
25. SV40-transformed hamster prostatic tissue: a model of human prostatic malignancy.
Paulson DF; Fraley EE; Rabson AS; Ketcham AS
Surgery; 1968 Jul; 64(1):241-7. PubMed ID: 4298081
[No Abstract] [Full Text] [Related]
26. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
27. [Soft agar culture of human prostatic carcinoma--effect of testosterone on the clonal growth of the cells].
Sakuramoto T; Kubota Y; Kitajima N; Hosaka M
Hinyokika Kiyo; 1985 Oct; 31(10):1717-21. PubMed ID: 4091120
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic studies of prostatic cancer.
Lundgren R
Scand J Urol Nephrol Suppl; 1991; 136():1-35. PubMed ID: 1871551
[TBL] [Abstract][Full Text] [Related]
29. Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate.
Landry F; Chapdelaine A; Bégin LR; Chevalier S
J Urol; 1996 Jan; 155(1):386-90. PubMed ID: 7490893
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
31. Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates.
Lobaccaro JM; Boudon C; Lechevallier E; Mottet N; Rebillard X; Lumbroso S; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):511-8. PubMed ID: 8828906
[TBL] [Abstract][Full Text] [Related]
32. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
33. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
34. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
[TBL] [Abstract][Full Text] [Related]
35. Transplantable metastasizing prostate adenocarcinomas in rats.
Pollard M; Luckert PH
J Natl Cancer Inst; 1975 Mar; 54(3):643-9. PubMed ID: 1123852
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145.
Durocher Y; Chapdelaine A; Chevalier S
Cancer Res; 1989 Sep; 49(17):4818-23. PubMed ID: 2474374
[TBL] [Abstract][Full Text] [Related]
39. Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2'-deoxyuridine) in human prostate tumors.
Sinha AA; Quast BJ; Wilson MJ; Reddy PK; Fernandes ET; Ewing SL; Gleason DF
Anticancer Res; 1998; 18(3A):1385-92. PubMed ID: 9673345
[TBL] [Abstract][Full Text] [Related]
40. 5'-nucleotidase activity in prostatic carcinoma and benign prostatic hyperplasia.
Rackley RR; Lewis TJ; Preston EM; Delmoro CM; Bradley EL; Resnick MI; Pretlow TP; Pretlow TG
Cancer Res; 1989 Jul; 49(13):3702-7. PubMed ID: 2471588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
